Pitavastatin patient counseling information

Revision as of 21:14, 17 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Pitavastatin}} {{CMG}}; {{AE}} {{SS}} ==Patient Counseling Information== The patient should be informed of the following: ===Dosing Time=== LIVALO can be taken ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Pitavastatin
LIVALO® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Pitavastatin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Patient Counseling Information

The patient should be informed of the following:

Dosing Time

LIVALO can be taken at any time of the day with or without food.

Muscle Pain

Patients should be advised to promptly notify their physician of any unexplained muscle pain, tenderness, or weakness particularly if accompanied by malaise or fever, or if these muscle signs or symptoms persist after discontinuing LIVALO. They should discuss all medication, both prescription and over the counter, with their physician.

Pregnancy

Women of childbearing age should use an effective method of birth control to prevent pregnancy while using LIVALO. Discuss future pregnancy plans with your healthcare professional, and discuss when to stop LIVALO if you are trying to conceive. If you are pregnant, stop taking LIVALO and call your healthcare professional.

Breastfeeding

Women who are breastfeeding should not use LIVALO. If you have a lipid disorder and are breastfeeding, stop taking LIVALO and consult with your healthcare professional.

Liver Enzymes

It is recommended that liver enzyme tests be checked before the initiation of LIVALO and if signs or symptoms of liver injury occur. All patients treated with LIVALO should be advised to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.[1]

References

  1. "LIVALO (PITAVASTATIN CALCIUM) TABLET, FILM COATED [KOWA PHARMACEUTICALS AMERICA, INC. ]". Retrieved 14 February 2014.

Template:Statins